1Department of Psychiatry, Zibo City Fifth People’s Hospital, Zibo 255100, China
2Department of Medical Records, The First Hospital of Zibo, Zibo 255200, China
3Institute of Integrative Medicine,Qingdao University Medical College, Qingdao 266021,China
4Shandong Public Health Clinical Center, Shandong University, Jinan 250013, China
American Journal of Pharmacological Sciences.
2024,
Vol. 12 No. 3, 40-45
DOI: 10.12691/ajps-12-3-3
Copyright © 2024 Science and Education PublishingCite this paper: Qian Ma, Bao Nan, Xi Yu, Qing-tao Ren, Qing-hua Zhang. Clinical Efficacy of Dengyin Naotong Capsule for Cognitive Impairment Related to Cerebral Small Vascular Disease.
American Journal of Pharmacological Sciences. 2024; 12(3):40-45. doi: 10.12691/ajps-12-3-3.
Correspondence to: Qing-hua Zhang, Shandong Public Health Clinical Center, Shandong University, Jinan 250013, China. Email:
zhang.qinghua@outlook.comAbstract
Objective: This study aims to investigate the clinical efficacy of Dengyin Naotong (DYNT) capsule for cognitive impairment related to cerebral small vascular disease (CSVS). Methods: Total of 105 patients with cognitive impairment related to CSVD hospitalized in Zibo Fifth People's Hospital from July 2021 to June 2023 were selected and randomly divided into control group (53 cases) and treatment group (52 cases). The patients in control group were treated with anti-arteriosclerosis, anti-platelet aggregation, nicergoline treatment, etc. while in treatment group combined with DYNT capsule on the basis of control group for 6 months both in the two groups. Before and after treatment, the Mini-mental State Examination (MMSE), Montreal Cognitive Assessment Scale (MoCA), Ability of Daily Living (ADL) score, Tinetti Balance and Gait Assessment Scale (POMA) score, Traditional Chinese Medicine Syndrome Scores (TCMSS), and the plasma levels of homocysteine (Hcy), C reactive protein (CRP) and D-dimer of patients were observed. Results: After treatment, the MMSE scores, MoCA scores ADL scores and POMA scores of patients increased significantly than those before treatment (P<0.05) both in the two groups, and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the TCMSS of patients decreased significantly than those before treatment (P<0.05) both in the two groups, and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the plasma levels of Hcy, CPR and D-dimer both in the two groups were significantly lower than before treatment (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion: DYNT capsule has some clinical efficacy in the treatment of cognitive impairment related to CSVD.
Keywords